{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-053099","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.169025+00:00","generated_at":"2026-06-08T03:25:34.937555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PDS Biotech Q3 net loss $10.8M; highlights 74% 2-year OS in VERSATILE-002 trial","bullets":["Net loss of $10.8M ($0.35/share) vs $7.4M loss in Q3 2022; R&D expenses rose to $6.4M from $4.4M.","Cash $54.3M at Sept 30, expected to fund operations into Q3 2024; VERSATILE-003 Phase 3 initiation planned Q1 2024.","VERSATILE-002 interim: 24-month overall survival rate of 74% in ICI-naïve HPV+ head & neck cancer patients.","NCI triple combo: 75% of ICI-naïve HPV+ cancer patients alive at 36 months; median OS not reached.","PDS01ADC+docetaxel: PSA decreased in all 18 prostate cancer patients; 61% had ≥60% PSA decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-053099","json":"https://secwatch.observer/filing/0001140361-23-053099.json","markdown":"https://secwatch.observer/filing/0001140361-23-053099.md","text":"https://secwatch.observer/filing/0001140361-23-053099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/0001140361-23-053099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/ef20014629_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:25:34.937555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10c74d72cfd16ae452b9e23a8f0a09f7876b43a6","claim":"PDS Biotechnology Corp reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, PDS Biotechnology Corporation (the “Company”) issued a press release announcing its financial results as of and for the three and nine months ended September 30, 2023 and provided an update on the business of the Company.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/0001140361-23-053099-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}